Antibiotic resistance is a public health threat of the utmost importance, especially when it comes to children: according to WHO data, infections caused by multidrug resistant bacteria produce 700,000 deaths across all ages, of which around 200,000 are newborns. This surging issue has multipronged roots that are specific to the pediatric age. For instance, the problematic overuse and misuse of antibiotics (for wrong diagnoses and indications, or at wrong dosage) is also fueled by the lack of pediatric-specific data and trials. The ever-evolving nature of this age group also poses another issue: the partly age-dependent changes of a developing system of cytochromes determine a rather diverse population in terms of biochemical characteristics and pharmacokinetics profiles, hard to easily codify in an age- or weight-dependent dosage. The pediatric population is also penalized by the contraindications of tetracyclines and fluoroquinolones, and by congenital malformations which often require repeated hospitalizations and pharmacological and surgical treatments from a very young age. Emerging threats for the pediatric age are MRSA, VRSA, ESBL-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae and the alarming colistin resistance. Urgent actions need to be taken in order to step back from a now likely post-antibiotic era, where simple infections might cause infant death once again.

Antibiotic resistance in pediatric infections: Global emerging threats, predicting the near future / A. Romandini, A. Pani, P.A. Schenardi, G. Angela Carla Pattarino, C. De Giacomo, F. Scaglione. - In: ANTIBIOTICS. - ISSN 2079-6382. - 10:4(2021), pp. 393.1-393.12. [10.3390/antibiotics10040393]

Antibiotic resistance in pediatric infections: Global emerging threats, predicting the near future

A. Romandini
Primo
;
A. Pani
Secondo
;
P.A. Schenardi;F. Scaglione
Ultimo
2021

Abstract

Antibiotic resistance is a public health threat of the utmost importance, especially when it comes to children: according to WHO data, infections caused by multidrug resistant bacteria produce 700,000 deaths across all ages, of which around 200,000 are newborns. This surging issue has multipronged roots that are specific to the pediatric age. For instance, the problematic overuse and misuse of antibiotics (for wrong diagnoses and indications, or at wrong dosage) is also fueled by the lack of pediatric-specific data and trials. The ever-evolving nature of this age group also poses another issue: the partly age-dependent changes of a developing system of cytochromes determine a rather diverse population in terms of biochemical characteristics and pharmacokinetics profiles, hard to easily codify in an age- or weight-dependent dosage. The pediatric population is also penalized by the contraindications of tetracyclines and fluoroquinolones, and by congenital malformations which often require repeated hospitalizations and pharmacological and surgical treatments from a very young age. Emerging threats for the pediatric age are MRSA, VRSA, ESBL-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae and the alarming colistin resistance. Urgent actions need to be taken in order to step back from a now likely post-antibiotic era, where simple infections might cause infant death once again.
Antibiotic resistance; Antibiotics; Antimicrobial stewardship; Childhood; Infections; Multidrug resistance
Settore BIO/14 - Farmacologia
2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
antibiotics-10-00393.pdf

accesso aperto

Descrizione: Review
Tipologia: Publisher's version/PDF
Dimensione 283.79 kB
Formato Adobe PDF
283.79 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/951980
Citazioni
  • ???jsp.display-item.citation.pmc??? 36
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 48
social impact